CIRB Studies

Below is the current list of studies covered by the CIRB. Participants should refer to ClinicalTrials.gov for general information about clinical trials. Institutions should refer to the Clinical Trials Support Unit (CTSU) website  for enrollment requirements and accrual status information. 

Study documents approved after July 1, 2013 are available to participating institutions for covered studies on the CTSU website. To request documents approved before July 1, 2013, participating institutions can contact the CIRB Helpdesk.

Review CIRB
Study Number Network Study Title CIRB
AGCT1532 COG Phase 3 Accelerated BEP Trial: A randomized phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumors Pediatric CIRB
AHEP0731 COG Treatment of Children with All Stages of Hepatoblastoma with Temsirolimus (IND#122782; NSC#683864) Added to High Risk Stratum Treatment: A Groupwide Phase III Study Pediatric CIRB
AHEP1531 COG Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT) Pediatric CIRB
AHOD03P1 COG Treatment of Children with Newly-Diagnosed Low Stage Lymphocyte Predominant Hodgkin Disease (LPHD): A Groupwide Pilot Study Pediatric CIRB
AHOD0431 COG A Phase III Study for the Treatment of Children and Adolescents With Newly Diagnosed Low Risk Hodgkin Disease Pediatric CIRB
AHOD04B1 COG Hodgkin Disease (HD) Banking Study Pediatric CIRB
AHOD0521 COG A Phase II Study of Bortezomib (Velcade; PS-341; IND # 58443) in Combination with Ifosfamide/Vinorelbine in Pediatric Patients and Young Adults with Refractory/Recurrent Hodgkin Disease: A Groupwide Phase II Study Pediatric CIRB
AHOD0831 COG A Non-Randomized Phase III Study of Response Adapted Therapy for the Treatment of Children with Newly Diagnosed High Risk Hodgkin Lymphoma: A Groupwide Phase III Study Pediatric CIRB
AHOD1221 COG A Phase 1/2 Study of Brentuximab Vedotin (SGN35; IND# 117117) in Combination with Gemcitabine for Pediatric and Young Adult Patients with Relapsed or Refractory Hodgkin Lymphoma Pediatric CIRB
AHOD1331 COG A Randomized Phase III Study of Brentuximab Vedotin (SGN-35; IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents: A Groupwide Phase III Study Pediatric CIRB